Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads heart traces to find silent liver danger

NCT ID NCT05782283

Completed Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether an artificial intelligence (AI) tool, called ACE 2.0, can detect undiagnosed liver cirrhosis by analyzing a routine electrocardiogram (ECG). Researchers at Mayo Clinic enrolled 279 primary care clinicians and their adult patients. The AI flagged ECGs that might indicate advanced liver disease, and doctors were alerted. The goal was to see if this approach leads to more early diagnoses compared to usual care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AI-powered ECG tool (ACE 2.0)
What this could lead to
If it works, this could give doctors a simple, cheap way to catch serious liver disease early, before it causes major damage.
What could go wrong
This was a small, early study (279 people) and only looked at detection, not treatment. The AI might miss cases or cause unnecessary worry.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LIVER FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis fibrotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRRHOSIS

Contacts and locations

Locations

  • Mayo Clinic Minnesota

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.